Literature DB >> 4043668

Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Analysis of 1063 specimens.

Y Matsuyama, M Omata, O Yokosuka, F Imazeki, Y Ito, K Okuda.   

Abstract

Hepatitis B virus DNA was determined in 1063 serum samples from 252 patients with hepatitis B surface antigen by the spot hybridization technique. The results were correlated with hepatitis B e antigen and antibody. Hepatitis B virus DNA was detected in 87% of hepatitis B e antigen-positive patients, in 18% of hepatitis B e antibody-positive patients, and in 18% of those negative for both. Discordance of antigen/antibody and hepatitis B virus DNA, i.e., the presence of the DNA in antibody-positive sera or the absence of the DNA in antigen-positive sera, was observed in 209 of 997 (21%) samples. Of 121 patients with histologic diagnosis, this discordance was observed in none of 20 patients with nonspecific changes, in 13% of 39 with chronic persistent hepatitis, in 21% of 38 with chronic active hepatitis, and in 38% of 24 with cirrhosis. Thus, hepatitis B e antigen/antibody testing alone failed to predict the presence or absence of circulating hepatitis B virion in a significant proportion of patients with advanced chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043668     DOI: 10.1016/0016-5085(85)90216-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  9 in total

1.  Prevalence of HBeAg, anti-HBe serological markers and HBV-DNA in asymptomatic carriers in Ethiopia.

Authors:  M Rapicetta; K Hailù; G Morace; L Bisanti; A M Di Rienzo; A R Ciccaglione; D Bekura; P Pasquini; G B Rossi
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

2.  Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Yoko Sakamoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Concentrating missense mutations in core gene of hepatitis B virus. Evidence for adaptive mutation in chronic hepatitis B virus infection.

Authors:  W L Chuang; M Omata; T Ehata; O Yokosuka; M Ohto
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

4.  Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction.

Authors:  N Kato; O Yokosuka; M Omata; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers.

Authors:  K Fujiwara; O Yokosuka; T Ehata; W L Chuang; F Imazeki; H Saisho; M Omata
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

6.  Rapid and sensitive method for the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique.

Authors:  S Kaneko; S M Feinstone; R H Miller
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Infectivity of medical staff for hepatitis B.

Authors:  H Hofmann; W Tuma; F X Heinz; W Frisch-Niggemeyer; C Kunz
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

8.  Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay.

Authors:  S Kaneko; R H Miller; S M Feinstone; M Unoura; K Kobayashi; N Hattori; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

9.  The prevalence of serological markers, hepatitis B virus DNA and elevated serum amino transferase values in institutionalized mentally handicapped males and females: an epidemiological study of HBV infection in residents with Down's syndrome or other forms of mental deficiency.

Authors:  T J van Ditzhuijsen; F M Kleijnen; P J Rijntjes; A M van Loon; S H Yap
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.